SINOVAC's Varicella Vaccine Receives Marketing Authorization in Argentina

BEIJING, June 9, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, announced that its live attenuated varicella vaccine, developed by SINOVAC (Dalian) Vaccine Technology Co., Ltd., has been granted marketing authorization by Argentina's National Administration of Drugs, Foods and Medical Technology (ANMAT).

SINOVAC's varicella vaccine is the first from China to achieve the World Health Organization (WHO) Prequalification. It is also the first in its category in China to incorporate Phase III efficacy data into its official labeling. The approval in Argentina follows previous registrations in Peru, Lebanon, Kenya, and Macau in China. As one of South America's most rigorous regulatory authorities, ANMAT's authorization further validates the vaccine's safety, efficacy, and quality control standards.

Extensive post-market clinical research has reinforced the vaccine's profile. A study published in early 2023 demonstrated that the co-administration of SINOVAC's varicella vaccine and its inactivated Hepatitis A vaccine, Healive®, in 1-year-old children showed no difference in immunogenicity or safety compared to separate administrations. 

In response to the global trend of varicella shifting toward older age groups where the disease is often more severe SINOVAC received approval for an age expansion in June 2024. The vaccine is now indicated for all individuals aged 12 months and older. 

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.